Skip to main content
SIR 2026 Event Main banner

Categorical Course

Interventional Oncology

300 (advanced)
Categorical Course

Innovations in Ablation of Colorectal Liver Metastases

Monday, April 13, 2026
8:30 AM - 9:45 AM ET

This Categorical Course provides a practical, evidence-based update on curative-intent ablation for colorectal liver metastases (CLM). The session is designed for practicing interventional radiologists, early-career IRs, and trainees, with a strong emphasis on current scientific evidence, clinical decision-making, procedural technique, and integration of emerging technologies that are shaping the future of interventional oncology.

Learning Objectives:

  • Identify ideal candidates for curative-intent thermal ablation based on clinical and technical characteristics
  • Summarize key trial data (COLLISION, MAVERIC,) that inform survival and local outcomes following CLM ablation.
  • Apply evidence-based workflow strategies using software-based ablation confirmation and margin assessment (ACCLAIM, COVER-ALL, NEW-COMMET).; Evaluate the practical role of non-thermal technologies—IRE, histotripsy, PEF—in tumors not well served by traditional thermal ablation.; Assess how Y-90 segmentectomy and high-dose selective internal radiotherapy fit into the modern curative-intent paradigm for liver tumors.

Presentations:

  • 8:30 AM - 8:42 AM ET
    Who Is the Patient That Can Be Cured by Ablation?

    Co-Speaker: Thierry de Baere

  • 8:42 AM - 8:54 AM ET
    Ablation Trials Affecting Survival: COLLISION and MAVERIC

    Co-Speaker: Philippe L. Pereira, MD, PhD (he/him/his) – SLK Kliniken gGmbH Heilbronn

  • 8:54 AM - 9:06 AM ET
    Technique Mastery: COVER-ALL, ACCLAIM, NEW-COMMET

    Speaker: Vlasios S. Sotirchos, MD – Memorial Sloan Kettering Cancer Center

  • 9:06 AM - 9:18 AM ET
    Evolving Role of Y-90 as Local Cure

    Co-Speaker: Laura Crocetti, MD, PhD – Univ of Pisa

  • 9:18 AM - 9:30 AM ET
    Role of Emerging Modalities: IRE, Histotripsy, PEF

    Speaker: Peiman Habibollahi, MD – MD Anderson Cancer Center

  • 9:30 AM - 9:45 AM ET
    Panel Discussion & Audience Q&A